Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

BACKGROUND: Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of trea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Tang, Min, Foo, Jasmine, Gönen, Mithat, Guilhot, Joëlle, Mahon, François-Xavier, Michor, Franziska
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2012
Gaiak:
Original Articles and Brief Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487556/
https://ncbi.nlm.nih.gov/pubmed/22419579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062844
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak